What is trifluorothymidine?

Trifluorothymidine, also known as 5-trifluoromethyl-2'-deoxyuridine (TFT), is a chemotherapeutic agent that is used in the treatment of various types of cancer, including solid tumors, lymphoma, and leukemia. It is a nucleoside analogue that works by inhibiting DNA synthesis, thereby preventing the replication of cancer cells.

TFT is generally administered intravenously, although it can also be given orally in some cases. Because it is a potent inhibitor of DNA synthesis, it has a relatively high toxicity and is typically reserved for more aggressive forms of cancer that are resistant to other types of treatment.

While TFT has been shown to be effective in treating certain types of cancer, it can also cause a number of side effects, including nausea, vomiting, diarrhea, fatigue, skin rashes, and bone marrow suppression. Patients receiving TFT must be closely monitored by their healthcare providers to ensure that any side effects are identified and managed appropriately.